CHACAR-NK-201

N/A

Report date: 2026/05/11 20:01:57

Base Information

Drug NameCHACAR-NK-201

Drug Alias NameAllogeneic CAR-NKCHACAR-NK-201

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic

Mechanisms of ActionAnti-FOLR1

TargetsFolate receptor alpha

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCHA Biotech Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesCHA Biotech Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A